31 related articles for article (PubMed ID: 11523053)
1. Somatic
Shell J; Patel D; Powers A; Quezado M; Killian K; Meltzer P; Zhu J; Gaitanidis A; Karzai F; Neychev V; Green P; Kebebew E
J Endocr Soc; 2017 Sep; 1(9):1124-1134. PubMed ID: 29264567
[TBL] [Abstract][Full Text] [Related]
2. Analysis of PTPRK polymorphisms in association with risk and age at onset of Alzheimer's disease, cancer risk, and cholesterol.
Chen Y; Xu C; Harirforoosh S; Luo X; Wang KS
J Psychiatr Res; 2018 Jan; 96():65-72. PubMed ID: 28987514
[TBL] [Abstract][Full Text] [Related]
3. Utilization of ancillary studies in the cytologic diagnosis of biliary and pancreatic lesions: The Papanicolaou Society of Cytopathology Guidelines.
Layfield LJ; Ehya H; Filie AC; Hruban RH; Jhala N; Joseph L; Vielh P; Pitman MB
Cytojournal; 2014; 11(Suppl 1):4. PubMed ID: 25191518
[TBL] [Abstract][Full Text] [Related]
4. Novel prognostic markers revealed by a proteomic approach separating benign from malignant insulinomas.
Alkatout I; Friemel J; Sitek B; Anlauf M; Eisenach PA; Stühler K; Scarpa A; Perren A; Meyer HE; Knoefel WT; Klöppel G; Sipos B
Mod Pathol; 2015 Jan; 28(1):69-79. PubMed ID: 24947143
[TBL] [Abstract][Full Text] [Related]
5. Utilization of ancillary studies in the cytologic diagnosis of biliary and pancreatic lesions: the Papanicolaou Society of Cytopathology guidelines for pancreatobiliary cytology.
Layfield LJ; Ehya H; Filie AC; Hruban RH; Jhala N; Joseph L; Vielh P; Pitman MB;
Diagn Cytopathol; 2014 Apr; 42(4):351-62. PubMed ID: 24639398
[TBL] [Abstract][Full Text] [Related]
6. MSH2 and CXCR4 involvement in malignant VIPoma.
Müller S; Kupka S; Königsrainer I; Northoff H; Sotlar K; Bock T; Kandolf R; Traub F; Königsrainer A; Zieker D
World J Surg Oncol; 2012 Dec; 10():264. PubMed ID: 23231927
[TBL] [Abstract][Full Text] [Related]
7. Molecular evidence for the bi-clonal origin of neuroendocrine tumor derived metastases.
Rinner B; Gallè B; Trajanoski S; Fischer C; Hatz M; Maierhofer T; Michelitsch G; Moinfar F; Stelzer I; Pfragner R; Guelly C
BMC Genomics; 2012 Nov; 13():594. PubMed ID: 23127113
[TBL] [Abstract][Full Text] [Related]
8. Localization of sporadic neuroendocrine tumors by gene expression analysis of their metastases.
Posorski N; Kaemmerer D; Ernst G; Grabowski P; Hoersch D; Hommann M; von Eggeling F
Clin Exp Metastasis; 2011 Oct; 28(7):637-47. PubMed ID: 21681495
[TBL] [Abstract][Full Text] [Related]
9. Chromosome 3p alterations in pancreatic endocrine neoplasia.
Amato E; Barbi S; Malpeli G; Bersani S; Pelosi G; Capelli P; Scarpa A
Virchows Arch; 2011 Jan; 458(1):39-45. PubMed ID: 20981439
[TBL] [Abstract][Full Text] [Related]
10. Insulin secretion and insulin-producing tumors.
Guettier JM; Gorden P
Expert Rev Endocrinol Metab; 2010 Mar; 5(2):217-227. PubMed ID: 20401170
[TBL] [Abstract][Full Text] [Related]
11. Pancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumors.
Halfdanarson TR; Rubin J; Farnell MB; Grant CS; Petersen GM
Endocr Relat Cancer; 2008 Jun; 15(2):409-27. PubMed ID: 18508996
[TBL] [Abstract][Full Text] [Related]
12. Molecular genetic events in gastrointestinal and pancreatic neuroendocrine tumors.
Lubensky IA; Zhuang Z
Endocr Pathol; 2007; 18(3):156-62. PubMed ID: 18041590
[TBL] [Abstract][Full Text] [Related]
13. Molecular profiles of gastroenteropancreatic endocrine tumors.
Perren A; Anlauf M; Komminoth P
Virchows Arch; 2007 Aug; 451 Suppl 1():S39-46. PubMed ID: 17684763
[TBL] [Abstract][Full Text] [Related]
14. Criteria for malignancy in gastrointestinal endocrine tumors.
Bordi C; D'Adda T; Azzoni C; Pizzi S; Bottarelli L; Mormandi F; Antonetti T; Luong TV; Rindi G
Endocr Pathol; 2006; 17(2):119-29. PubMed ID: 17159244
[TBL] [Abstract][Full Text] [Related]
15. Xq25 and Xq26 identify the common minimal deletion region in malignant gastroenteropancreatic endocrine carcinomas.
Azzoni C; Bottarelli L; Pizzi S; D'Adda T; Rindi G; Bordi C
Virchows Arch; 2006 Feb; 448(2):119-26. PubMed ID: 16244870
[TBL] [Abstract][Full Text] [Related]
16. Historical, current and future perspectives on gastrointestinal and pancreatic endocrine tumors.
van Eeden S; Offerhaus GJ
Virchows Arch; 2006 Jan; 448(1):1-6. PubMed ID: 16220293
[TBL] [Abstract][Full Text] [Related]
17. Putative tumor suppressor loci at 6q22 and 6q23-q24 are involved in the malignant progression of sporadic endocrine pancreatic tumors.
Barghorn A; Speel EJ; Farspour B; Saremaslani P; Schmid S; Perren A; Roth J; Heitz PU; Komminoth P
Am J Pathol; 2001 Jun; 158(6):1903-11. PubMed ID: 11395364
[TBL] [Abstract][Full Text] [Related]
18. Deletion at 3p25.3-p23 is frequently encountered in endocrine pancreatic tumours and is associated with metastatic progression.
Barghorn A; Komminoth P; Bachmann D; Rütimann K; Saremaslani P; Muletta-Feurer S; Perren A; Roth J; Heitz PU; Speel EJ
J Pathol; 2001 Aug; 194(4):451-8. PubMed ID: 11523053
[TBL] [Abstract][Full Text] [Related]
19. Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis.
Clifford SC; Prowse AH; Affara NA; Buys CH; Maher ER
Genes Chromosomes Cancer; 1998 Jul; 22(3):200-9. PubMed ID: 9624531
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
